SCHEMBL30005503

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C

nearest known ligand 0.77

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	20/20	0.77

▸	ECE1	P42892	1/20	0.77

▸	MUS81	Q96NY9	1/20	0.77

▸	CCKBR	P32239	1/20	0.71

▸	GCGR	P47871	1/20	0.70

▸	GIPR	P48546	1/20	0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29558511	0.97	GLP1R (0.77)	GLP1RECE1MUS81CCKBR
SCHEMBL29942531	0.96	GLP1R (0.78)	GLP1RECE1MUS81CCKBRGCGR
SCHEMBL30216755	0.95	GLP1R (0.72)	GLP1RECE1MUS81CCKBRGCGR
SCHEMBL29454666	0.94	GLP1R (0.75)	GLP1RECE1MUS81CCKBRGCGR
SCHEMBL30726557	0.94	GLP1R (0.70)	GLP1RECE1MUS81CCKBRGCGR
SCHEMBL30874399	0.94	GLP1R (0.75)	GLP1RECE1MUS81CCKBRGCGR
SCHEMBL30721601	0.94	GLP1R (0.77)	GLP1RECE1MUS81CCKBR
SCHEMBL29634677	0.94	GLP1R (0.77)	GLP1RECE1MUS81CCKBR
SCHEMBL29498823	0.94	GLP1R (0.77)	GLP1RECE1MUS81CCKBR
SCHEMBL31047778	0.94	GLP1R (0.78)	GLP1RECE1MUS81CCKBRGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-4090355-A1	COMBINATIONAL THERAPY COMPRISING GLP-1 AND/OR GLP-1 ANALOGS, AND INSULIN AND/OR INSULIN ANALOGS	Shanghai Benemae Pharmaceutical Corporation (CN)	2022-11-23	—	—	EP	disclosed